Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction : the VICTORIA echocardiographic substudy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084040" target="_blank" >RIV/00023001:_____/23:00084040 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2836" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2836</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.2836" target="_blank" >10.1002/ejhf.2836</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction : the VICTORIA echocardiographic substudy

Popis výsledku v původním jazyce

Aim Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. Methods and results Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co-primary endpoints were changes in LV end-systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high-quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 +/- 26.8 to 56.8 +/- 30.4ml/m(2); p &lt; 0.01) and LVEF significantly increased (33.0 +/- 9.4% to 36.1 +/- 10.2%; p &lt; 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI -3.8 +/- 15.4 vs. -7.1 +/- 20.5ml/m(2); p= 0.07 and LVEF +3.2 +/- 8.0% vs. +2.4 +/- 7.6%; p= 0.31). The absolute rate per 100 patient-years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p= 0.07). Conclusions In this pre-specified echocardiographic study, significant improvements in LV structure and function occurred over 8months in both vericiguat and placebo in a high-risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat&apos;s benefit in HFrEF. [GRAPHICS] .

Název v anglickém jazyce

Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction : the VICTORIA echocardiographic substudy

Popis výsledku anglicky

Aim Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. Methods and results Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co-primary endpoints were changes in LV end-systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high-quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 +/- 26.8 to 56.8 +/- 30.4ml/m(2); p &lt; 0.01) and LVEF significantly increased (33.0 +/- 9.4% to 36.1 +/- 10.2%; p &lt; 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI -3.8 +/- 15.4 vs. -7.1 +/- 20.5ml/m(2); p= 0.07 and LVEF +3.2 +/- 8.0% vs. +2.4 +/- 7.6%; p= 0.31). The absolute rate per 100 patient-years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p= 0.07). Conclusions In this pre-specified echocardiographic study, significant improvements in LV structure and function occurred over 8months in both vericiguat and placebo in a high-risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat&apos;s benefit in HFrEF. [GRAPHICS] .

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European journal of heart failure

ISSN

1388-9842

e-ISSN

1879-0844

Svazek periodika

25

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

1012-1021

Kód UT WoS článku

000974501600001

EID výsledku v databázi Scopus

2-s2.0-85153709765